Healthcare / BiotechnologyTokyo
$240.00
-11.00 (-4.38%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 24%
FCF escenarios
weak_data · normalized FCF $-884.5M · quality 72.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$9.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-87.0%
↓Gross Margin
51.1%
↑Debt/Equity
0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-12.9%
FCF CAGR
—
FCF margin
-1213.8%
FCF / Net income
0.92x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $83.7M · net income $-1.10B · FCF $-1.02B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $83.7M | $83.7M | $193.3M | $190.1M | $126.4M |
| Net Income | $-1.10B | $-1.10B | $-859.8M | $-846.5M | $-759.7M |
| EBITDA | $-1.10B | $-1.10B | $-855.5M | $-836.5M | $-750.0M |
| EPS | — | — | -25.72 | -29.43 | -36.31 |
| Gross Margin | 51.1% | 51.1% | 57.0% | 56.4% | 48.3% |
| Operating Margin | -1250.2% | -1250.2% | -437.9% | -367.0% | -587.9% |
| Net Margin | -1319.5% | -1319.5% | -444.9% | -445.2% | -600.9% |
| Balance Sheet | |||||
| Debt/Equity | 0.10 | 0.10 | 0.07 | 0.07 | 0.13 |
| Current Ratio | 6.36 | 6.36 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.02B | $-1.02B | $-884.5M | $-801.1M | $-733.6M |
| Returns | |||||
| ROE | -87.0% | -87.0% | -39.7% | -39.1% | -64.5% |
| Valuation | |||||
| P/B | 6.57 | 6.57 | 6.17 | 3.56 | 3.02 |
| Growth & Yield | |||||
| Revenue Growth | -56.7% | -56.7% | 1.7% | 50.4% | — |
| EPS Growth | — | — | 12.6% | 18.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-55.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-25.72 → n/d
Residual
-55.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.